Travere Therapeutics, Inc. (TVTX) earnings date
Feb 18, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 67% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-18
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 34 days, typically, give or take 8 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Mon, Nov 2, 2026 | after close | 33 | 8-K |
| Q2 FY2026 | Tue, Aug 4, 2026 | after close | 35 | 8-K |
| Q1 FY2026 | Mon, May 4, 2026 | after close | 34 | 8-K |
| Q4 FY2025 | Thu, Feb 19, 2026 | after close | 50 | 8-K |
| Q3 FY2025 | Thu, Oct 30, 2025 | after close | 30 | 8-K |
| Q2 FY2025 | Wed, Aug 6, 2025 | after close | 37 | 8-K |
| Q4 FY2024 | Thu, Feb 20, 2025 | after close | 51 | 8-K |
| Q3 FY2024 | Thu, Oct 31, 2024 | before open | 31 | 8-K |
What they guided beta
| Q3 FY2026 | "Upon issuance, the patent is expected to provide U.S. patent coverage for certain methods of using sparsentan in FSGS into October 2037." exhibit |
| Q2 FY2026 | "Document Exhibit 99.1 Contact: Investors: Media: 888-969-7879 888-969-7879 IR@travere.com mediarelations@travere.com Travere Therapeutics Reports Second Quarter 2026 Financial Results Strong FSGS launch and continued IgAN growth drive robust FILSPARI demand; 2,012 new PSFs received during the second quarter U.S. net product sales of FILSPARI grew 96% year-over-year to $141 million Enrollment of pegtibatinase Phase 3 HARMONY Study in HCU continues; Topline data expected in 2H 2027 In-licensing of civorebrutinib expands long-term growth opportunities in multiple immune-mediated rare kidney disea" exhibit |
| Q2 FY2026 | "Upon issuance, the patent is expected to provide U.S. patent coverage for certain methods of using sparsentan in IgA nephropathy into October 2037." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/TVTX
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/TVTX
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/TVTX/"><img src="https://veritasdata.dev/embed/TVTX.svg" alt="TVTX earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/TVTX/)
Script
<script async src="https://veritasdata.dev/embed/TVTX.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/TVTX"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.